LITMUS Molecular Design

LITMUS Molecular Design (LMD) creates and characterizes molecular entities.

LMD is a subsidiary of LITMUS, LLC using a proprietary technology (LITMUS Spectral ModelingTM) to accurately predict a molecule's:

  • Chemical reactivity
  • Biological activity
  • Receptor binding affinity
  • Toxicity, carcinogenicity
  • Metabolism
  • Absorption/through-membrane transmission,
  • and chemical and physical properties,

  based upon spectral information versus structural characteristics as with most drug discovery methods.

Using this approach, LMD has designed three groups of compounds available for out licensing for development:

  • Antipsychotics
  • HSP-90 cancer therapy
  • Orexin 1